EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detection of a major Lynch Syndrome-causing MLH1 founder variant in a large-scale genotyped cohort

Lauri J Sipilä, Mervi Aavikko, Janne Ravantti, Samantha Martin, Teijo Kuopio, Laura Lahtinen, FinnGen, Päivi Peltomäki, Jukka-Pekka Mecklin, Lauri A Aaltonen, Toni T Seppälä

Familial Cancer · 2024

DOI: 10.1007/s10689-024-00400-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Familial Cancer, 2024. Verfasst von Lauri J Sipilä und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Clinical Genetics, University of Helsinki, Biomedicum Helsinki Haartmaninkatu 8), PO Box 63, 00014, Helsinki, Finland. Hauptthemen laut MEDLINE: MutL Protein Homolog 1, Colorectal Neoplasms, Hereditary Nonpolyposis, Genotype. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Finland (Finnish Centre of Excellence Program), Jane and Aatos Erkko Foundation, iCAN Digital Precision Cancer Medicine Flagship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Some 50% of Finnish Lynch Syndrome (LS) cases are caused by a founder variant in MLH1 , in which the entire exon 16 has been lost due to an Alu-mediated recombination event. We piloted detecting the variant in FinnGen, a large genotyped cohort comprising approximately 10% of the current Finnish population, and validated the MLH1 founder variant status of identified individuals residing in the Central Finland Biobank catchment area. A consensus sequence flanking the deletion was identified in whole genome sequences of six LS individuals with the founder variant. Genotype data of 212,196 individuals was queried for regional matches to the consensus sequence. Enrichment of cancer and age at cancer onset was compared between matching and non-matching individuals. Variant status was validated for a subset of the identified individuals using a polymerase chain reaction assay. Allelic matches in a chosen target region was detected in 348 individuals, with 89 having a cancer diagnosis (Bonferroni-adjusted p-value = 1), 20 a familial cancer history (p-adj. < .001), with mean age of onset of cancer being 53.6 years (p-adj. = .002). Eighteen of potential variant carriers had been sampled by the Central Finland Biobank, of which four (22%) were validated as true variant carriers. The workflow we have employed identifies MLH1 exon 16 deletion variant carriers from population-wide SNP genotyping data. An alternative design will be sought to limit false positive findings. Large genotyped cohorts provide a potential resource for identification and prevention of hereditary cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutL Protein Homolog 1Colorectal Neoplasms, Hereditary NonpolyposisGenotypeHumansFinlandMiddle AgedFemaleMaleCohort StudiesFounder EffectAdultAgedAge of OnsetGenetic Predisposition to DiseaseExons

Stichwörter der Autor:innen

BiobankGenotype associationLynch syndromeMismatch repair deficiencyPersonalized medicine

Substanzen

MutL Protein Homolog 1MLH1 protein, human

Autor:innen und Institutionen

  • Department of Medical and Clinical Genetics, University of Helsinki, Biomedicum Helsinki Haartmaninkatu 8), PO Box 63, 00014, Helsinki, Finland.
  • Applied Tumor Genomics, Research Programs Unit, University of Helsinki, Biomedicum Helsinki Haartmaninkatu 8), PO Box 63, 00014, Helsinki, Finland.
  • Finnish Cancer Registry, Unioninkatu 22, 00130, Helsinki, Finland.
  • Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
  • Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, FI-00014, Helsinki, Finland.
  • Central Finland Biobank, Wellbeing Services County of Central Finland and University of Jyväskylä, Jyväskylä, Finland.

Förderung

  • Research Council of Finland (Finnish Centre of Excellence Program)
  • Jane and Aatos Erkko Foundation
  • iCAN Digital Precision Cancer Medicine Flagship
  • Cancer Foundation Finland
  • University of Helsinki

Zitieren

APA

Sipilä, L. J., Aavikko, M., Ravantti, J., Martin, S., Kuopio, T., Lahtinen, L., FinnGen, Peltomäki, P., Mecklin, J. P., Aaltonen, L. A., & Seppälä, T. T. (2024). Detection of a major Lynch Syndrome-causing MLH1 founder variant in a large-scale genotyped cohort. Familial Cancer. https://doi.org/10.1007/s10689-024-00400-4

Vancouver

Sipilä LJ, Aavikko M, Ravantti J, Martin S, Kuopio T, Lahtinen L, et al. Detection of a major Lynch Syndrome-causing MLH1 founder variant in a large-scale genotyped cohort. Familial Cancer. 2024. doi:10.1007/s10689-024-00400-4

BibTeX
@article{Sipil2024,
  author = {Sipilä, Lauri J and Aavikko, Mervi and Ravantti, Janne and Martin, Samantha and Kuopio, Teijo and Lahtinen, Laura and FinnGen and Peltomäki, Päivi and Mecklin, Jukka-Pekka and Aaltonen, Lauri A and Seppälä, Toni T},
  title = {Detection of a major Lynch Syndrome-causing MLH1 founder variant in a large-scale genotyped cohort},
  journal = {Familial Cancer},
  year = {2024},
  doi = {10.1007/s10689-024-00400-4}
}
Kostenlos starten →